-
Je něco špatně v tomto záznamu ?
Negative Prognostic Impact of Smoking on Long-term Survival in Patients With Nasopharyngeal Carcinoma Treated With Curative (Chemo)radiotherapy
M. Pala, P. Novakova, T. Drbohlavova, A. Vrana, Z. Pechacova, K. Votavova, A. Subrt, D. Krejci, P. Holeckova, P. Tesarova
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články
NLK
Free Medical Journals
od 2004 do Před 2 roky
PubMed Central
od 2017
Europe PubMed Central
od 2017
Open Access Digital Library
od 2004-01-01
PubMed
37369456
DOI
10.21873/invivo.13266
Knihovny.cz E-zdroje
- MeSH
- chemoradioterapie MeSH
- kouření škodlivé účinky MeSH
- lidé MeSH
- nádory nosohltanu * farmakoterapie patologie MeSH
- nasofaryngeální karcinom terapie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND/AIM: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with nasopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes. PATIENTS AND METHODS: We conducted a retrospective study of 73 consecutive patients, treated with definitive (chemo)radiotherapy from 2002 to 2019 (median stage III/IV 78%). The median total dose of radiotherapy achieved was 70 Gy. Concomitant chemotherapy was given to 82% of patients. RESULTS: The five- and ten-year locoregional controls were 73% and 72%, respectively; the five- and ten-year distant controls were 93% and 93%, respectively. The five- and ten-year overall survival rates were 46% and 34%, respectively. A multivariate analysis identified age, smoking, and the initial response to treatment as the strongest prognostic factors in predicting survival. CONCLUSION: Smoking ≤5 years before starting curative (chemo)radiotherapy for nasopharyngeal carcinoma was shown to be an independent negative prognostic factor for overall survival with a four-fold higher risk of death compared to non-smokers.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010864
- 003
- CZ-PrNML
- 005
- 20240621085836.0
- 007
- ta
- 008
- 230718s2023 gr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.21873/invivo.13266 $2 doi
- 035 __
- $a (PubMed)37369456
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Pala, Miloslav $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic; miloslav.pala@bulovka.cz
- 245 10
- $a Negative Prognostic Impact of Smoking on Long-term Survival in Patients With Nasopharyngeal Carcinoma Treated With Curative (Chemo)radiotherapy / $c M. Pala, P. Novakova, T. Drbohlavova, A. Vrana, Z. Pechacova, K. Votavova, A. Subrt, D. Krejci, P. Holeckova, P. Tesarova
- 520 9_
- $a BACKGROUND/AIM: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with nasopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes. PATIENTS AND METHODS: We conducted a retrospective study of 73 consecutive patients, treated with definitive (chemo)radiotherapy from 2002 to 2019 (median stage III/IV 78%). The median total dose of radiotherapy achieved was 70 Gy. Concomitant chemotherapy was given to 82% of patients. RESULTS: The five- and ten-year locoregional controls were 73% and 72%, respectively; the five- and ten-year distant controls were 93% and 93%, respectively. The five- and ten-year overall survival rates were 46% and 34%, respectively. A multivariate analysis identified age, smoking, and the initial response to treatment as the strongest prognostic factors in predicting survival. CONCLUSION: Smoking ≤5 years before starting curative (chemo)radiotherapy for nasopharyngeal carcinoma was shown to be an independent negative prognostic factor for overall survival with a four-fold higher risk of death compared to non-smokers.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nasofaryngeální karcinom $x terapie $7 D000077274
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory nosohltanu $x farmakoterapie $x patologie $7 D009303
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a kouření $x škodlivé účinky $7 D012907
- 650 _2
- $a chemoradioterapie $7 D059248
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Novakova, Pavla $u Radiophysics Department of Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Drbohlavova, Tereza $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Vrana, Antonin $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Pechacova, Zdenka $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Votavová, Karolína $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic $7 xx0319041
- 700 1_
- $a Subrt, Adam $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Krejci, Daniel $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Holeckova, Petra $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic
- 700 1_
- $a Tesarova, Petra $u Institute of Radiation Oncology of the 1 Faculty of Medicine Charles University and Bulovka University Hospital, Prague, Czech Republic $u Department of Oncology of the 1st Faculty of Medicine Charles University and General University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00175831 $t In Vivo $x 1791-7549 $g Roč. 37, č. 4 (2023), s. 1775-1785
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37369456 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20240621085837 $b ABA008
- 999 __
- $a ok $b bmc $g 1963336 $s 1197129
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 37 $c 4 $d 1775-1785 $e - $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
- LZP __
- $a Pubmed-20230718